NASDAQ:ONCE - Spark Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$78.30 -0.72 (-0.91 %)
(As of 05/25/2018 01:06 PM ET)
Previous Close$78.06
Today's Range$76.67 - $78.91
52-Week Range$41.06 - $91.75
Volume5,885 shs
Average Volume628,022 shs
Market Capitalization$2.92 billion
P/E Ratio-10.12
Dividend YieldN/A
Beta2.54

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. The company's products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A. In addition, its product candidates and development programs include SPK-FVIII program to treat hemophilia A; SPK-TPP1 program for the treatment of CLN2 disease; RhoNova for the treatment of rhodopsin-linked autosomal dominant retinitis pigmentosa; and other neurodegenerative diseases. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.

Receive ONCE News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCE
CUSIPN/A
Phone888-772-7560

Debt

Debt-to-Equity RatioN/A
Current Ratio11.37
Quick Ratio11.27

Price-To-Earnings

Trailing P/E Ratio-10.12
Forward P/E Ratio-22.83
P/E GrowthN/A

Sales & Book Value

Annual Sales$12.07 million
Price / Sales242.55
Cash FlowN/A
Price / CashN/A
Book Value$12.83 per share
Price / Book6.10

Profitability

EPS (Most Recent Fiscal Year)($7.63)
Net Income$-253,480,000.00
Net Margins-935.38%
Return on Equity-51.76%
Return on Assets-42.28%

Miscellaneous

Employees315
Outstanding Shares37,390,000

Spark Therapeutics (NASDAQ:ONCE) Frequently Asked Questions

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics (NASDAQ:ONCE) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($0.45) by $0.80. The biotechnology company earned $15.68 million during the quarter, compared to the consensus estimate of $51.55 million. Spark Therapeutics had a negative net margin of 935.38% and a negative return on equity of 51.76%. Spark Therapeutics's quarterly revenue was up 1134.6% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.70) earnings per share. View Spark Therapeutics' Earnings History.

What price target have analysts set for ONCE?

21 brokerages have issued 1 year target prices for Spark Therapeutics' shares. Their forecasts range from $40.00 to $113.00. On average, they expect Spark Therapeutics' share price to reach $76.10 in the next year. View Analyst Ratings for Spark Therapeutics.

What are Wall Street analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:
  • 1. Raymond James analysts commented, "We are maintaining our Outperform rating for Spark. Hemophilia (WFH) 2018 World Congress, the company, along with its partner, Pfizer, provided an update on the ongoing Phase I/II study evaluating SPK-9001 for hemophilia B (Hem B). In addition, Spark’s competitor, BioMarin, provided an update on the ongoing Phase I/II trial of valoctocogene roxaparvovec (or BMN 270) in severe hemophilia A (Hem A)." (5/23/2018)
  • 2. Mizuho analysts commented, "We expect the update to be an important catalyst given the large market opportunity in this indication. We expect to see data from three-dose cohorts and a longer follow-up time since the last update at the Hematology (ASH) in December 2017. Management is also advancing preparations for a phase 3 trial in parallel." (5/8/2018)
  • 3. Cantor Fitzgerald analysts commented, "Updates to our Model. We are increasing our PT to $103/share from $100, based on the adjustment to our estimate of 2018 YE net cash. This increase is driven by a year-end cash increase from $549 million to $659 million ($18/ share), which accounts for the $110 million increase (a $3/share increase)." (4/30/2018)

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:
  • Mr. Jeffrey D. Marrazzo M.B.A., M.P.A., Co-Founder, CEO & Director (Age 39)
  • Dr. Katherine A. High, Co-Founder, Pres and Chief Scientific Officer (Age 66)
  • Mr. Stephen W. Webster, Chief Financial Officer (Age 57)
  • Mr. John Furey, Chief Operating Officer (Age 53)
  • Mr. Daniel R. Faga, Chief Bus. Officer (Age 38)

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse acted as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Has Spark Therapeutics been receiving favorable news coverage?

News articles about ONCE stock have been trending very positive on Friday, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Spark Therapeutics earned a news impact score of 0.52 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 47.94 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are Spark Therapeutics' major shareholders?

Spark Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.08%), Federated Investors Inc. PA (4.02%), Rock Springs Capital Management LP (1.67%), Sofinnova Ventures Inc (1.29%), OppenheimerFunds Inc. (1.14%) and Rockefeller Capital Management L.P. (0.96%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Institutional Ownership Trends for Spark Therapeutics.

Which institutional investors are selling Spark Therapeutics stock?

ONCE stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Wells Fargo & Company MN, Eventide Asset Management LLC, Element Capital Management LLC, SG Americas Securities LLC, Guggenheim Capital LLC, Jane Street Group LLC and BlackRock Inc.. Company insiders that have sold Spark Therapeutics company stock in the last year include Anand Mehra, Barge Joseph La, Daniel Faga, Hospital Of Philade Children's, Jeffrey D Marrazzo, John Furey, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Which institutional investors are buying Spark Therapeutics stock?

ONCE stock was bought by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, Rockefeller Capital Management L.P., PointState Capital LP, Pinnacle Associates Ltd., OppenheimerFunds Inc., UBS Group AG, Point72 Asset Management L.P. and Amundi Pioneer Asset Management Inc.. View Insider Buying and Selling for Spark Therapeutics.

How do I buy shares of Spark Therapeutics?

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of ONCE stock can currently be purchased for approximately $78.30.

How big of a company is Spark Therapeutics?

Spark Therapeutics has a market capitalization of $2.92 billion and generates $12.07 million in revenue each year. The biotechnology company earns $-253,480,000.00 in net income (profit) each year or ($7.63) on an earnings per share basis. Spark Therapeutics employs 315 workers across the globe.

How can I contact Spark Therapeutics?

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]


MarketBeat Community Rating for Spark Therapeutics (ONCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  346 (Vote Outperform)
Underperform Votes:  274 (Vote Underperform)
Total Votes:  620
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe ONCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Spark Therapeutics (NASDAQ:ONCE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
21 Wall Street analysts have issued ratings and price targets for Spark Therapeutics in the last 12 months. Their average twelve-month price target is $76.10, suggesting that the stock has a possible downside of 2.81%. The high price target for ONCE is $113.00 and the low price target for ONCE is $40.00. There are currently 1 sell rating, 7 hold ratings and 13 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.572.702.752.83
Ratings Breakdown: 1 Sell Rating(s)
7 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $76.10$71.8947$69.8421$91.5294
Price Target Upside: 2.81% downside11.67% downside36.04% upside31.96% upside

Spark Therapeutics (NASDAQ:ONCE) Consensus Price Target History

Price Target History for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018Raymond JamesReiterated RatingBuyHighView Rating Details
5/22/2018Cantor FitzgeraldSet Price TargetBuy$103.00HighView Rating Details
5/9/2018WedbushReiterated RatingUnderperform$40.00LowView Rating Details
5/9/2018BMO Capital MarketsSet Price TargetOutperform ➝ Buy$64.00 ➝ $78.00HighView Rating Details
5/9/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$64.00 ➝ $76.00HighView Rating Details
5/9/2018Royal Bank of CanadaBoost Price TargetOutperform$75.00HighView Rating Details
5/9/2018BarclaysReiterated RatingPositive ➝ Overweight$64.00 ➝ $85.00HighView Rating Details
5/8/2018CowenReiterated RatingBuy$85.00HighView Rating Details
5/8/2018MizuhoReiterated RatingBuy$91.00HighView Rating Details
5/7/2018Leerink SwannReiterated RatingMarket Perform$55.00HighView Rating Details
5/1/2018JPMorgan Chase & Co.Boost Price TargetNeutral ➝ Neutral$60.00 ➝ $63.00LowView Rating Details
5/1/2018CitigroupInitiated CoverageNeutral ➝ Neutral$85.00MediumView Rating Details
4/23/2018Chardan CapitalDowngradeBuy ➝ Neutral$80.00 ➝ $85.00HighView Rating Details
4/19/2018William BlairReiterated RatingBuyLowView Rating Details
3/8/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$61.00 ➝ $75.00MediumView Rating Details
2/21/2018Sanford C. BernsteinReiterated RatingBuy$71.00 ➝ $60.00LowView Rating Details
1/4/2018SunTrust BanksBoost Price TargetBuy$113.00HighView Rating Details
12/14/2017Goldman Sachs GroupDowngradeBuy ➝ Neutral$106.00 ➝ $58.00LowView Rating Details
12/12/2017UBSDowngradeBuy ➝ Neutral$92.00 ➝ $51.00HighView Rating Details
10/10/2017Jefferies GroupReiterated RatingBuy$95.00N/AView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn ➝ In-Line$83.00HighView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Spark Therapeutics (NASDAQ:ONCE) Earnings History and Estimates Chart

Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ:ONCE) Earnings Estimates

2018 EPS Consensus Estimate: ($3.70)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185($1.71)$1.20($0.99)
Q2 20185($1.50)$1.08($0.91)
Q3 20185($1.02)($0.46)($0.78)
Q4 20185($1.62)($0.08)($1.02)

Spark Therapeutics (NASDAQ ONCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.45)($1.25)$51.55 million$15.68 millionViewN/AView Earnings Details
2/20/2018Q4 2017($1.73)($1.73)$9.53 million$7.41 millionViewListenView Earnings Details
11/7/2017Q3 2017($1.79)($1.90)$1.40 million$1.90 millionViewN/AView Earnings Details
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Spark Therapeutics (NASDAQ:ONCE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Spark Therapeutics (NASDAQ ONCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 5.90%
Insider Trading History for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics (NASDAQ ONCE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2018John FureyCOOSell6,723$82.50$554,647.506,723View SEC Filing  
4/18/2018John FureyCOOSell13,277$82.52$1,095,618.042,277View SEC Filing  
4/12/2018John FureyCOOSell20,000$77.51$1,550,200.0020,000View SEC Filing  
12/11/2017John FureyCOOSell18$46.33$833.94View SEC Filing  
12/8/2017John FureyCOOBuy18$73.48$1,322.64View SEC Filing  
11/28/2017Katherine A HighInsiderSell5,000$71.32$356,600.00215,000View SEC Filing  
11/16/2017Stephen W WebsterCFOSell10,000$70.14$701,400.0012,500View SEC Filing  
11/13/2017Barge Joseph LaInsiderSell5,500$71.44$392,920.008,146View SEC Filing  
11/13/2017Jeffrey D MarrazzoCEOSell20,000$71.54$1,430,800.00250,000View SEC Filing  
11/9/2017Barge Joseph LaInsiderSell3,309$71.31$235,964.798,146View SEC Filing  
10/31/2017Katherine A HighInsiderSell5,000$83.30$416,500.00215,000View SEC Filing  
10/24/2017Daniel FagaInsiderSell7,500$80.96$607,200.006,000View SEC Filing  
10/20/2017Daniel FagaInsiderSell6,000$79.95$479,700.006,000View SEC Filing  
9/26/2017Katherine A HighInsiderSell5,000$86.16$430,800.00215,000View SEC Filing  
9/21/2017Hospital Of Philade Children'sDirectorSell1,000,000$84.63$84,630,000.003,928,707View SEC Filing  
9/19/2017Daniel FagaInsiderSell1,500$85.00$127,500.001,500View SEC Filing  
9/12/2017Daniel FagaInsiderSell6,000$82.50$495,000.006,000View SEC Filing  
9/7/2017Daniel FagaInsiderSell3,000$85.02$255,060.003,000View SEC Filing  
9/5/2017Barge Joseph LaInsiderSell5,500$81.00$445,500.0010,825View SEC Filing  
8/29/2017Katherine A HighInsiderSell10,000$80.25$802,500.00220,000View SEC Filing  
8/23/2017Jeffrey D MarrazzoCEOSell21,350$80.01$1,708,213.50251,350View SEC Filing  
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.0012,500View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00245,000View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50258,650View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.444,837View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00220,000View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.003,000View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00235,669View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.004,500View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00220,000View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00230,534View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00220,000View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.0010,163View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.009,567View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00212,060View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.004,398View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60212,060View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.004,398View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.0010,325View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.0010,325View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.008,325View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00210,000View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00235,000View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.008,325View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00240,000View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00220,500View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.005,768,707View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80236,971View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00240,000View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00230,100View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00242,290View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60242,348View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20246,017View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44242,348View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66246,017View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00235,000View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.0019,716View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.008,325View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.006,768,707View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00235,000View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00270,100View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.0012,825View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.0022,500View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00255,000View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.0019,716View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.907,768,707View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.007,900,212View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00280,000View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00290,000View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00300,000View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00300,000View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00230,000View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00305,000View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.005,383View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.002,500View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.005,000View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Spark Therapeutics (NASDAQ ONCE) News Headlines

Source:
DateHeadline
Wired News - Spark Therapeutics and Pfizer Announced Positive Data from Phase-1/2 Clinical Trial of SPK-9001 for Haemophilia B TreatmentWired News - Spark Therapeutics and Pfizer Announced Positive Data from Phase-1/2 Clinical Trial of SPK-9001 for Haemophilia B Treatment
finance.yahoo.com - May 24 at 8:39 AM
Cantor Fitzgerald Research Analysts Raise Earnings Estimates for Spark Therapeutics (ONCE)Cantor Fitzgerald Research Analysts Raise Earnings Estimates for Spark Therapeutics (ONCE)
www.americanbankingnews.com - May 24 at 8:34 AM
Spark Therapeutics (ONCE) Given Buy Rating at Raymond JamesSpark Therapeutics (ONCE) Given Buy Rating at Raymond James
www.americanbankingnews.com - May 23 at 1:01 PM
Spark, Pfizer report progress on gene therapy for hemophiliaSpark, Pfizer report progress on gene therapy for hemophilia
finance.yahoo.com - May 22 at 5:16 PM
Spark Therapeutics (ONCE) Given a $103.00 Price Target by Cantor Fitzgerald AnalystsSpark Therapeutics (ONCE) Given a $103.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 22 at 9:45 AM
Sparks gene therapy SPK-9001 shows treatment benefit in hemophilia B studySpark's gene therapy SPK-9001 shows treatment benefit in hemophilia B study
seekingalpha.com - May 22 at 8:10 AM
Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse EventsSpark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
finance.yahoo.com - May 22 at 8:10 AM
 Brokerages Expect Spark Therapeutics (ONCE) Will Post Quarterly Sales of $42.61 Million Brokerages Expect Spark Therapeutics (ONCE) Will Post Quarterly Sales of $42.61 Million
www.americanbankingnews.com - May 19 at 3:02 AM
 Brokerages Expect Spark Therapeutics (ONCE) Will Announce Earnings of -$0.39 Per Share Brokerages Expect Spark Therapeutics (ONCE) Will Announce Earnings of -$0.39 Per Share
www.americanbankingnews.com - May 17 at 1:14 PM
Pennsylvania’s Amish community is caught in a bindPennsylvania’s Amish community is caught in a bind
www.msn.com - May 14 at 9:55 AM
Research Analysts Offer Predictions for Spark Therapeutics Q2 2018 Earnings (ONCE)Research Analysts Offer Predictions for Spark Therapeutics' Q2 2018 Earnings (ONCE)
www.americanbankingnews.com - May 14 at 2:00 AM
High Growth AMEX Stocks For The DayHigh Growth AMEX Stocks For The Day
finance.yahoo.com - May 12 at 5:19 PM
Jefferies Group Weighs in on Spark Therapeutics Q2 2018 Earnings (ONCE)Jefferies Group Weighs in on Spark Therapeutics' Q2 2018 Earnings (ONCE)
www.americanbankingnews.com - May 11 at 8:35 AM
Recent Developments, Recommendations for JAZZ in MayRecent Developments, Recommendations for JAZZ in May
finance.yahoo.com - May 10 at 5:15 PM
Spark Therapeutics (ONCE) Given Consensus Rating of "Buy" by BrokeragesSpark Therapeutics (ONCE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 10 at 1:43 PM
Edited Transcript of ONCE earnings conference call or presentation 8-May-18 12:30pm GMTEdited Transcript of ONCE earnings conference call or presentation 8-May-18 12:30pm GMT
finance.yahoo.com - May 10 at 8:41 AM
Q2 2018 EPS Estimates for Spark Therapeutics (ONCE) Raised by AnalystQ2 2018 EPS Estimates for Spark Therapeutics (ONCE) Raised by Analyst
www.americanbankingnews.com - May 10 at 6:36 AM
Q2 2018 Earnings Estimate for Spark Therapeutics (ONCE) Issued By Leerink SwannQ2 2018 Earnings Estimate for Spark Therapeutics (ONCE) Issued By Leerink Swann
www.americanbankingnews.com - May 10 at 6:36 AM
Spark Therapeutics (ONCE) Receives Underperform Rating from WedbushSpark Therapeutics (ONCE) Receives Underperform Rating from Wedbush
www.americanbankingnews.com - May 9 at 6:59 PM
BMO Capital Markets Increases Spark Therapeutics (ONCE) Price Target to $78.00BMO Capital Markets Increases Spark Therapeutics (ONCE) Price Target to $78.00
www.americanbankingnews.com - May 9 at 6:03 PM
Stifel Nicolaus Increases Spark Therapeutics (ONCE) Price Target to $76.00Stifel Nicolaus Increases Spark Therapeutics (ONCE) Price Target to $76.00
www.americanbankingnews.com - May 9 at 4:43 PM
Royal Bank of Canada Boosts Spark Therapeutics (ONCE) Price Target to $75.00Royal Bank of Canada Boosts Spark Therapeutics (ONCE) Price Target to $75.00
www.americanbankingnews.com - May 9 at 3:12 PM
Spark Therapeutics (ONCE) Earns Overweight Rating from BarclaysSpark Therapeutics (ONCE) Earns Overweight Rating from Barclays
www.americanbankingnews.com - May 9 at 1:29 PM
Q3 2018 EPS Estimates for Spark Therapeutics Boosted by Analyst (ONCE)Q3 2018 EPS Estimates for Spark Therapeutics Boosted by Analyst (ONCE)
www.americanbankingnews.com - May 9 at 7:56 AM
Cowen Reaffirms "Buy" Rating for Spark Therapeutics (ONCE)Cowen Reaffirms "Buy" Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - May 8 at 9:15 PM
Spark Therapeutics (ONCE) Given "Buy" Rating at MizuhoSpark Therapeutics (ONCE) Given "Buy" Rating at Mizuho
www.americanbankingnews.com - May 8 at 5:27 PM
Spark Therapeutics (ONCE) CEO Jeff Marrazzo on Q1 2018 Results - Earnings Call TranscriptSpark Therapeutics' (ONCE) CEO Jeff Marrazzo on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 5:21 PM
Spark Therapeutics (ONCE) Given a $103.00 Price Target at Cantor FitzgeraldSpark Therapeutics (ONCE) Given a $103.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 8 at 3:28 PM
Spark Therapeutics (ONCE) Posts  Earnings Results, Misses Estimates By $0.80 EPSSpark Therapeutics (ONCE) Posts Earnings Results, Misses Estimates By $0.80 EPS
www.americanbankingnews.com - May 8 at 9:34 AM
Spark Therapeutics misses by $0.84, misses on revenueSpark Therapeutics misses by $0.84, misses on revenue
seekingalpha.com - May 8 at 8:40 AM
Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business ProgressSpark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
finance.yahoo.com - May 8 at 8:40 AM
Spark Therapeutics: 1Q Earnings SnapshotSpark Therapeutics: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 8:40 AM
Spark Therapeutics (ONCE) "Market Perform" Rating Reiterated at Leerink SwannSpark Therapeutics' (ONCE) "Market Perform" Rating Reiterated at Leerink Swann
www.americanbankingnews.com - May 7 at 2:58 PM
16 Stocks Moving In Mondays Pre-Market Session16 Stocks Moving In Monday's Pre-Market Session
www.benzinga.com - May 7 at 9:26 AM
$53.82 Million in Sales Expected for Spark Therapeutics (ONCE) This Quarter$53.82 Million in Sales Expected for Spark Therapeutics (ONCE) This Quarter
www.americanbankingnews.com - May 2 at 5:36 AM
Spark Therapeutics (ONCE) PT Raised to $63.00Spark Therapeutics (ONCE) PT Raised to $63.00
www.americanbankingnews.com - May 1 at 10:42 AM
Spark Therapeutics (ONCE) Now Covered by CitigroupSpark Therapeutics (ONCE) Now Covered by Citigroup
www.americanbankingnews.com - May 1 at 9:08 AM
Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - May 1 at 8:08 AM
Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business HighlightsSpark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights
finance.yahoo.com - May 1 at 8:08 AM
Mizuho Reaffirms Buy Rating for Spark Therapeutics (ONCE)Mizuho Reaffirms Buy Rating for Spark Therapeutics (ONCE)
www.americanbankingnews.com - May 1 at 6:36 AM
Spark Therapeutics (ONCE) PT Set at $103.00 by Cantor FitzgeraldSpark Therapeutics (ONCE) PT Set at $103.00 by Cantor Fitzgerald
www.americanbankingnews.com - April 30 at 11:08 AM
Voucher sale brings $110M payday for Spark TherapeuticsVoucher sale brings $110M payday for Spark Therapeutics
finance.yahoo.com - April 30 at 9:50 AM
Spark Therapeutics Sells Priority Review Voucher for $110 MillionSpark Therapeutics Sells Priority Review Voucher for $110 Million
finance.yahoo.com - April 30 at 9:50 AM
-$0.45 Earnings Per Share Expected for Spark Therapeutics (ONCE) This Quarter-$0.45 Earnings Per Share Expected for Spark Therapeutics (ONCE) This Quarter
www.americanbankingnews.com - April 30 at 1:16 AM
John Furey Sells 6,723 Shares of Spark Therapeutics (ONCE) StockJohn Furey Sells 6,723 Shares of Spark Therapeutics (ONCE) Stock
www.americanbankingnews.com - April 24 at 7:32 PM
Portlands Casey Eye Institute enlists ground-breaking gene therapyPortland's Casey Eye Institute enlists ground-breaking gene therapy
www.bizjournals.com - April 23 at 5:03 PM
Spark Therapeutics (ONCE) Downgraded by Chardan CapitalSpark Therapeutics (ONCE) Downgraded by Chardan Capital
www.americanbankingnews.com - April 23 at 8:12 AM
Spark Therapeutics ground-breaking gene therapy now being administered at select hospitalsSpark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
www.bizjournals.com - April 20 at 8:33 AM
Spark Therapeutics' ground-breaking gene therapy now being administered at select hospitalsSpark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
finance.yahoo.com - April 20 at 8:33 AM
Insider Selling: Spark Therapeutics (ONCE) COO Sells 13,277 Shares of StockInsider Selling: Spark Therapeutics (ONCE) COO Sells 13,277 Shares of Stock
www.americanbankingnews.com - April 19 at 7:19 PM

SEC Filings

Spark Therapeutics (NASDAQ:ONCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Spark Therapeutics (NASDAQ:ONCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Spark Therapeutics (NASDAQ ONCE) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.